Trial Profile
Effect of interferon-free direct acting antivirals combination therapy on innate immune responses in patients with chronic hepatitis C infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
- 07 Feb 2017 New trial record